Inhaled Nitric Oxide for Premature Infants with Severe Respiratory Failure
- 7 July 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (1) , 13-22
- https://doi.org/10.1056/nejmoa043927
Abstract
Inhaled nitric oxide is a controversial treatment for premature infants with severe respiratory failure. We conducted a multicenter, randomized, blinded, controlled trial to determine whether inhaled nitric oxide reduced the rate of death or bronchopulmonary dysplasia in such infants. We randomly assigned 420 neonates, born at less than 34 weeks of gestation, with a birth weight of 401 to 1500 g, and with respiratory failure more than four hours after treatment with surfactant to receive placebo (simulated flow) or inhaled nitric oxide (5 to 10 ppm). Infants with a response (an increase in the partial pressure of arterial oxygen of more than 10 mm Hg) were weaned according to protocol. Treatment with study gas was discontinued in infants who did not have a response. The rate of death or bronchopulmonary dysplasia was 80 percent in the nitric oxide group, as compared with 82 percent in the placebo group (relative risk, 0.97; 95 percent confidence interval, 0.86 to 1.06; P=0.52), and the rate of bronchopulmonary dysplasia was 60 percent versus 68 percent (relative risk, 0.90; 95 percent confidence interval, 0.75 to 1.08; P=0.26). There were no significant differences in the rates of severe intracranial hemorrhage or periventricular leukomalacia. Post hoc analyses suggest that rates of death and bronchopulmonary dysplasia are reduced for infants with a birth weight greater than 1000 g, whereas infants weighing 1000 g or less who are treated with inhaled nitric oxide have higher mortality and increased rates of severe intracranial hemorrhage. The use of inhaled nitric oxide in critically ill premature infants weighing less than 1500 g does not decrease the rates of death or bronchopulmonary dysplasia. Further trials are required to determine whether inhaled nitric oxide benefits infants with a birth weight of 1000 g or more.Keywords
This publication has 30 references indexed in Scilit:
- Early inhaled nitric oxide in moderately hypoxemic preterm and term newborns with RDS: the RDS subgroup analysis of the Franco-Belgian iNO Randomized Trial.European Journal of Pediatrics, 2003
- Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trialThe Lancet, 1999
- Early compared with delayed inhaled nitric oxide in moderately hypoxaemic neonates with respiratory failure: a randomised controlled trialThe Lancet, 1999
- Atypical Chronic Lung Disease Patterns in NeonatesPediatrics, 1999
- Effects of Inhaled Nitric Oxide on Pulmonary Edema and Lung Neutrophil Accumulation in Severe Experimental Hyaline Membrane DiseasePediatric Research, 1997
- Echocardiographic investigation of inhaled nitric oxide in newborn babies with severe hypoxaemiaThe Lancet, 1994
- Inhaled Nitric Oxide for the Adult Respiratory Distress SyndromeNew England Journal of Medicine, 1993
- Pulmonary and systemic arterial pressure in hyaline membrane disease.Archives of Disease in Childhood, 1992
- Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.Circulation, 1991
- Doppler assessment of pulmonary artery pressure and extrapulmonary shunting in the acute phase of hyaline membrane disease.Archives of Disease in Childhood, 1991